Skip to main
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 36%
Buy 23%
Hold 36%
Sell 5%
Strong Sell 0%

Bulls say

Biogen is expected to have a strong future due to its diverse portfolio, including successful treatments for multiple sclerosis and promising candidates in late-stage development for Alzheimer's and lupus. Despite potential risks in the immunology field, the company has shown a dedication to innovation and community impact which has contributed to positive market response and outlook. With consistent revenue growth from its established franchises and potential new additions, Biogen has the potential for strong financial performance in the coming years.

Bears say

Biogen is facing several challenges that could impact its stock performance in the near and long term. These include a declining multiple sclerosis franchise, reliance on one revenue-generating collaboration agreement with Roche, and heavy competition in the rare disease space. The potential success of its newer franchises is uncertain, and their market potential may not be significant enough to offset the declines in the company's core MS business. Additionally, there are risks related to clinical failures or reimbursement limitations for key pipeline products, as well as potential negative impacts from competition, generics, and pricing pressures. Despite recent strategic initiatives and potential upside from its Alzheimer's franchise, these challenges may continue to weigh on Biogen's stock performance.

Biogen (BIIB) has been analyzed by 22 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 23% recommend Buy, 36% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 22 analysts, Biogen (BIIB) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $214.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $214.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.